Korean J Med.  2014 Jul;87(1):9-13.

Glucagon-Like Peptide-1 (GLP-1) Agonist

• Eom YS
• Kim BJ

Abstract

The prevalence of diabetes is increasing worldwide. Glycemic control has been shown to prevent microvascular complications. Many oral hyperglycemic drugs and insulin are being used in the treatment of diabetes, but the effects of those treatments are suboptimal. The two incretin hormones GLP-1 and GIP are released from L- and K-cells, respectively, in response to nutrient intake. GLP-1 stimulates glucose-dependent insulin release. Recently, incretin hormone-based therapies, including GLP-1 agonists and DPP-4 inhibitors, have been used as new treatment options to control glucose levels in patients with type 2 diabetes mellitus. The purpose of this article is to review the efficacy and safety of GLP-1 agonists in the treatment of type 2 diabetes.

Keyword

Glucagon-like peptide 1 analogue; Incretin; Type 2 diabetes

MeSH Terms

Diabetes Mellitus, Type 2
Glucagon-Like Peptide 1*
Glucose
Humans
Incretins
Insulin
Prevalence
Glucagon-Like Peptide 1
Glucose
Incretins
Insulin